Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study
Safety and Tolerability of Anisodine Hydrobromide in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib, Open-Label, Nonrandomized, 3+3 Dose-Escalation Study
This study is an investigator-initiated Phase Ib clinical trial employing a prospective, single-center, open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of anisodine hydrobromide in patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment and to determine the recommended dose for subsequent clinical studies.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is an investigator-initiated, prospective, single-center Phase Ib clinical trial designed to evaluate the safety and tolerability of anisodine hydrobromide administered to patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment. The trial adopts an open-label, non-randomized, 3+3 dose-escalation design to identify the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D).
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yu Feng, MD, PhD
- Phone Number: +86-15252148124
- Email: xyfysjnkfy@126.com
Study Contact Backup
- Name: Zihao Jiao
- Phone Number: +86-17596062986
- Email: medicinejzh@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 80 years.
- Diagnosis of acute ischemic stroke.
- Time from stroke onset to first dose of study medication ≤24 hours.
- Imaging-confirmed acute vertebrobasilar artery occlusion (VBAO), including basilar artery occlusion, bilateral intracranial vertebral artery occlusion, or vertebrobasilar tandem occlusion.
- Eligible for and planned to undergo emergency endovascular treatment.
- Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6.
- Posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS) ≥6.
- No definite extensive irreversible infarction on posterior circulation imaging assessment.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent obtained from the participant or their legally authorized representative.
Exclusion Criteria:
- Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
- History of congenital or acquired bleeding disorders, coagulation factor deficiencies, or thrombocytopenic disorders.
- Vascular anatomical conditions expected to prevent successful completion of endovascular treatment.
- Known severe allergy to iodinated contrast media.
- Pregnancy or breastfeeding, or planning to become pregnant during the study period or within 90 days after enrollment.
- Known allergy to anisodine hydrobromide or a history of severe intolerance following previous administration.
- Concomitant clinical conditions that may be exacerbated by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention, prostatic hypertrophy with difficulty urinating, or paralytic ileus.
- Severe cardiac arrhythmias (e.g., tachyarrhythmias requiring electrical cardioversion or recurrent syncope) or hemodynamic instability (e.g., requiring vasopressors or persistent hypotension).
- Severe psychiatric disorders, dementia, or impaired consciousness that would prevent the participant from providing informed consent or completing follow-up.
- Malignancy or other severe systemic diseases with an expected survival of less than 90 days.
- Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Anisodine Hydrobromide 1.0 mg
Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes. |
Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization. In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated. |
|
Experimental: Anisodine Hydrobromide 1.5 mg
Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes. |
Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization. In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated. |
|
Experimental: Anisodine Hydrobromide 2.0 mg
Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes. |
Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization. In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated. |
|
Experimental: Anisodine Hydrobromide 2.5 mg
Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes. |
Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization. In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Predefined Safety Events Within 8 Days
Time Frame: Within 8 days after the first administration
|
The primary safety outcome is the occurrence of predefined safety events within 8 consecutive days after the first administration of the study drug. Predefined safety events include: (1) symptomatic intracranial hemorrhage (sICH), defined as intracranial hemorrhage confirmed by neuroimaging in conjunction with neurological deterioration, operationalized as an increase of at least 4 points in the NIHSS score; (2) death from any cause; and (3) any other serious adverse event (SAE), excluding the foregoing events, that is adjudicated by the Data Monitoring Committee (DMC) to be definitely, probably, or possibly related to the study drug. |
Within 8 days after the first administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early Neurological Deterioration
Time Frame: Within 24 hours after treatment initiation
|
Early neurological deterioration is defined as worsening in neurological status within 24 hours after treatment initiation. Neurological status is assessed using the National Institutes of Health Stroke Scale (NIHSS), a validated clinical instrument for assessing stroke severity. The NIHSS total score ranges from 0 to 42, with higher scores indicating greater neurological impairment. |
Within 24 hours after treatment initiation
|
|
Infarct Volume
Time Frame: Day 8
|
Infarct volume measured on non-contrast cranial computed tomography (CT) at Day 8, expressed in milliliters (mL). |
Day 8
|
|
Functional Outcome (Modified Rankin Scale)
Time Frame: Day 90
|
Functional outcome assessed using the modified Rankin Scale (mRS) at Day 90. The mRS score ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The distribution of mRS scores will be reported. |
Day 90
|
|
Incidence of Symptomatic Intracranial Hemorrhage
Time Frame: Within 8 days after the first administration
|
Incidence of symptomatic intracranial hemorrhage (sICH) confirmed by neuroimaging and accompanied by neurological deterioration, defined as an increase of at least 4 points in the NIHSS score, within 8 days after the first administration of the study drug. |
Within 8 days after the first administration
|
|
Incidence of Any Intracranial Hemorrhage
Time Frame: Within 8 days after the first administration
|
Incidence of any intracranial hemorrhage detected by neuroimaging within 8 days after the first administration of the study drug, regardless of whether neurological deterioration is present. |
Within 8 days after the first administration
|
|
Incidence of Study Drug-Related Adverse Events
Time Frame: Within 90 days after the first administration
|
Incidence of adverse events (AEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide. |
Within 90 days after the first administration
|
|
Incidence of Study Drug-Related Serious Adverse Events
Time Frame: Within 90 days after the first administration
|
Incidence of serious adverse events (SAEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide. |
Within 90 days after the first administration
|
|
All-Cause Mortality
Time Frame: Within 90 days after the first administration
|
All-cause mortality occurring within 90 days after the first administration of the study drug. |
Within 90 days after the first administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yu Feng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University
- Study Director: Yanbo Cheng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XYFY2026-KL739-01-Ib
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.